[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fatigue\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fatigue":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,111,0,25,[9,50,87,119,140,169,194,224,257,279,318,338,365,386,420,444,474,498,526,552,577,605,638,666,692],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":34,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100648630","micro-choice-based-intervention-for-multicausal-fatigue-100648630",false,"NCT07726082","Micro-choice-based Intervention for Multicausal Fatigue","Micro-choice-based Intervention for Multicausal Fatigue: Proof of Concept Study","CHOOSE-POC","Inclusion Criteria:\n\n\\- Experiencing persistent fatigue with a significant impact on daily functioning (Chalder Fatigue- Scale bimodal ≥ 4)\n\nExclusion Criteria:\n\n* Have insufficient proficiency in German to complete study-related questionnaires\n* Lack the cognitive capacity to understand study procedures (e.g. due to dementia)\n* Present with severe medical conditions that may interfere with participation (e.g., advanced organ failure, uncontrolled inflammatory or autoimmune diseases, or severe psychiatric disorders)\n* Have active cancer or are currently undergoing cancer treatment\n* Are deemed incompatible with group participation during the preparation phase, based on a team assessment. Reasons for exclusion based on group incompatibility include:\n\n  1. Need for a level of individual therapeutic support that exceeds what can be provided in a group setting; b) Refusal to engage in group-based therapy; c) Personality traits that are considered incompatible with group dynamics; d) Failure to attend the mandatory preparatory webinar (no-show is considered a no-go); e) Other significant reasons as determined by the therapeutic team)","ALL","18 Years","65 Years",{"count":22,"type":23},24,"ESTIMATED","INTERVENTIONAL",[26],"NA","This proof-of-concept study aims to evaluate the feasibility, acceptability, and potential benefits of a novel multimodal approach: the micro-choice-based intervention.",[29,30,31,32,33],"Multicausal Fatigue","Fatigue","Post COVID Condition","Long COVID Syndrome","Postviral Fatigue",[35,36],"neuroplastic therapy","group intervention","RECRUITING","2026-08-14",{"date":40,"type":41},"2026-08-18","ACTUAL",{"date":43,"type":41},"2026-08-13",{"date":45,"type":23},"2027-08",{"name":47,"class":48},"University Hospital, Basel, Switzerland","OTHER",1,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":24,"phases":63,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":49},"100650851","effects-of-basketball-specific-interval-exercise-on-metabolic-inflammatory-and-fatigue-responses-in-female-basketball-players-100650851","NCT07752459","Physiological Responses to Basketball-Specific Interval Exercise in Female Basketball Players","The Effect of Basketball-Specific Interval Exercise on Metabolic and Inflammatory Responses, Energy Substrate Utilization, and Perceived Fatigue in Female Basketball Players","INTER-BASKET","Inclusion Criteria:\n\n* Female, aged 16-22 years.\n* Regular participation in organized basketball training.\n* Current medical clearance for sports participation.\n* No contraindications to high-intensity physical exercise.\n* Willingness and ability to provide written informed consent (and parental\u002Flegal guardian consent where required for minors).\n* Willingness to comply with all study procedures.\n* Menstrual cycle phase will be recorded for all participants and considered as a potential covariate in the statistical analyses.\n\nExclusion Criteria:\n\n* Current musculoskeletal injury or any condition preventing maximal exercise.\n* Metabolic, cardiovascular, inflammatory, or other chronic diseases affecting exercise capacity or study outcomes.\n* Current use of anti-inflammatory medications.\n* Use of supplements or substances that may influence the measured metabolic or inflammatory parameters.\n* Refusal to undergo blood sampling.\n* Failure to comply with pre-test instructions (e.g., dietary or exercise restrictions).",true,"FEMALE","16 Years","22 Years",{"count":7,"type":23},[26],"This study aims to evaluate the effects of interval exercise on metabolic and inflammatory responses, energy substrate utilization, and fatigue in trained female basketball players. High-intensity intermittent exercise is a key component of basketball performance and induces substantial metabolic and physiological stress. However, the acute relationships between exercise-induced metabolic changes, inflammatory responses, substrate utilization, and fatigue in female basketball players remain insufficiently understood.\n\nIn this prospective interventional study, eligible female basketball players will complete a standardized interval exercise protocol designed to replicate the physiological demands of competitive basketball. Physiological, biochemical, and perceptual measurements will be collected before exercise, immediately after exercise, and during recovery. Primary outcomes include changes in metabolic and inflammatory biomarkers, energy substrate utilization, and fatigue-related responses. Secondary outcomes include selected physiological and performance-related variables associated with recovery from high-intensity interval exercise.\n\nThe findings of this study will improve the understanding of the physiological responses to interval exercise in female basketball players and may contribute to the development of evidence-based training and recovery strategies aimed at optimizing performance and athlete health.",[66,30,67],"Exercise","Sport Physiology",[69,70,71,72,73,74,75,76],"basketball","Yo-Yo test","High-Intensity Interval Exercise","Reaction Time","Energy Metabolism","Free Fatty Acids","Exercise-Induced Fatigue","Female Athletes","NOT_YET_RECRUITING","2026-08-11",{"date":80,"type":41},"2026-08-12",{"date":82,"type":23},"2026-09-20",{"date":84,"type":23},"2026-12-30",{"name":86,"class":48},"Poznan University of Physical Education",{"id":88,"slug":89,"hasResults":12,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":24,"phases":96,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100645025","phase-3-a-phase-3-efficacy-and-safety-study-of-hbs-301-in-participants-with-narcolepsy-100645025","NCT07675135","A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy","A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy Followed by an Open-label Extension","Inclusion Criteria:\n\n* Has a current documented diagnosis of NT1 or NT2 per the International Classification of Sleep Disorders, Third Edition (ICSD-3) or the ICSD-3 Text Revision (ICSD-3-TR) within the last 10 years.\n* Has EDS.\n* If taking a permitted chronic concomitant medication or supplement, including nonprohibited antidepressants or wake-promoting agents, must be on a stable dose for at least 3 months prior to Screening and agree to continue at that stable dose for the Double-blind Treatment Period of the study. As needed (PRN) use of any treatment that could affect daytime sleepiness (including but not limited to oxybates, stimulants, modafinil, and armodafinil) is not permitted.\n\nExclusion Criteria:\n\n* Has hypersomnia due to another medical disorder.\n* Has a history of pitolisant use within 5 half-lives prior to Screening.\n* Has a primary diagnosis of psychiatric illness, including depression, that is not well controlled (i.e., symptoms and medications have not been stable for at least 3 months prior to Screening).\n* Has any history of bipolar disorder or psychosis\n* Has acute or chronic liver disease or a history of moderate or severe hepatic impairment.\n* Has a body surface area-corrected estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin.\n* Has a known history of long QT syndrome or serious abnormality of the electrocardiogram (ECG).",{"count":95,"type":23},258,[97],"PHASE3","This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in treating excessive daytime sleepiness (EDS), cataplexy, sleepiness\u002Fwakefulness, and fatigue in adult participants (ages ≥18 years) with narcolepsy.",[100,101,30,102],"EDS","Cataplexy","Narcolepsy",[104,105,106,100,107,108],"pitolisant","HBS-301","narcolepsy","cataplexy","fatigue","2026-08-10",{"date":80,"type":41},{"date":112,"type":41},"2026-06-04",{"date":114,"type":23},"2027-11",{"name":116,"class":117},"Harmony Biosciences Management, Inc.","INDUSTRY",50,{"id":120,"slug":121,"hasResults":12,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":24,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":49},"100607284","cancer-related-fatigue-and-its-biological-contributors-in-adolescent-and-young-adult-brain-tumor-survivors-effects-of-a-tele-exercise-intervention-100607284","NCT07186556","Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention","Inclusion Criteria:\n\n1. Is currently between the ages of 18-39 years\n2. Their primary brain tumor was diagnosed at age 15-39 years\n3. Is 6 months to \\\u003C5 years post curative treatment\n4. Has been treated with chemotherapy and radiation, given most patients receive both therapies.\n5. Functional Assessment of Chronic Illness therapy (FACIT)-Fatigue ≤ 43. FACIT-Fatigue will be used as a screener because this 13-item scale can be completed relatively quickly in clinic\n6. Currently engage in \\\u003C150 minutes of PA and \\\u003C 2 sessions of muscle strengthening exercise per week (assessed by Godin Leisure-Time PA Questionnaire)\n7. Must be able to speak, write, and read English\n8. No exercise contraindication as assessed by screening with the Physical Activity Readiness Questionnaire PAR-Q+. In addition, participants' care teams will be notified of their participation in the study.\n9. Must be able to provide informed consent\u002Fassent.\n\nExclusion Criteria:\n\n1. Non-English speaking\n2. Screen failure for exercise safety\n3. Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease\n4. Recent fracture or acute musculoskeletal injury that precludes ability to participate in supervised exercise training sessions\n5. History of underlying chronic disease, secondary malignances, germline genetic syndrome, or recurrent disease requiring re-irradiation of the brain\n6. Cognitive and\u002For major sensory deficits that would impede the completion of research activities and assessments as deemed by the clinical team.\n7. Self-report of pregnancy\n8. Prisoners\n9. Documented developmental disorders (e.g., Autism) or major psychotic illness (e.g., schizophrenia)","39 Years",{"count":127,"type":23},75,[26],"The goal of this research study is to learn about the effects of the RISE-YA intervention on cancer-related fatigue in young adults who are brain cancer survivors.",[131,30,132],"Cancer","Brain Tumor Adult",{"date":80,"type":41},{"date":135,"type":41},"2025-09-09",{"date":137,"type":23},"2031-12-31",{"name":139,"class":48},"M.D. Anderson Cancer Center",{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":18,"minAge":148,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":24,"phases":152,"briefSummary":155,"conditions":156,"keywords":158,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":49},"100562913","phase-1-bupropion-for-fatigue-in-end-stage-kidney-disease-patients-on-hemodialysis-100562913","NCT06609343","Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis","Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis (BRISK)","BRISK","Inclusion Criteria:\n\n1. Male and female ESKD patients between aged 25-74 yrs on maintenance in-center hemodialysis procedure 3 times\u002Fweek for ≥3 months with an arteriovenous fistula or graft.\n2. Blood hemoglobin of ≥10.0 g\u002FdL based on most recent routine laboratory profile.\n3. Dialysis adequacy measured with Kt\u002FV of ≥1.2\n4. Ability to understand and the willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Currently on bupropion or hypersensitivity\u002F intolerance to bupropion by history and monoamine oxidase inhibitors.\n2. Diagnosis or history of eating disorders (bulimia or anorexia nervosa) and seizure.\n3. Pregnant, lactating, childbearing women\n4. History of post-acute COVID-19 syndrome\n5. Diagnosis of depression and\u002For on antidepressants and bipolar affective disorder\n6. Patient Health Questionnaire (PHQ)-9 score of ≥10\n7. Diagnosis of cognitive impairment including dementia\n8. Current participation in another interventional trial\n9. Scheduled for kidney transplantation in next 6 months\n10. Life expectancy \\\u003C6 months as judged by the attending nephrologist\u002Fprimary care physician.\n11. Current or history of substance abuse or dependency.","25 Years","74 Years",{"count":151,"type":23},16,[153,154],"PHASE1","PHASE2","Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysis patients.\n\nIn this study, hemodialysis participants will receive bupropion tablet orally three times a week during routine dialysis procedure for consecutive 8 weeks. Study participants will complete a battery of questionnaires to self-report fatigue, cognition, and quality of life. The study team will collect biological specimens. All these procedures will be performed at the dialysis clinic during routine dialysis procedure.",[157,30],"End Stage Renal Disease",[159,160],"Hemodialysis","Kidney dialysis","2026-08-07",{"date":78,"type":41},{"date":164,"type":23},"2026-08-24",{"date":166,"type":23},"2027-01-30",{"name":168,"class":48},"The University of Texas Health Science Center at San Antonio",{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":58,"sex":59,"minAge":19,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":24,"phases":179,"briefSummary":180,"conditions":181,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":49},"100650431","effects-of-taekwondo-match-simulated-fatigue-on-balance-performance-in-female-athletes-100650431","NCT07747064","Effects of Taekwondo Match-Simulated Fatigue on Balance Performance in Female Athletes","Effects of Taekwondo Match-Simulated Fatigue on Static and Dynamic Balance Performance in Female Athletes","Inclusion Criteria:\n\n* Female taekwondo athletes aged 18-20 years.\n* Regular participation in taekwondo training (minimum 3 sessions per week).\n* Minimum of 3 years of competitive taekwondo experience.\n* Free from musculoskeletal injury at the time of testing.\n* Willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Any musculoskeletal injury within the previous 6 months.\n* Neurological, vestibular, or balance disorders.\n* Lower-extremity surgery within the previous 12 months.\n* Any medical condition preventing participation in maximal exercise.\n* Failure to complete the testing protocol","20 Years",{"count":178,"type":23},20,[26],"Taekwondo is a high-intensity combat sport characterized by repeated explosive kicking actions and rapid changes in body position, requiring well-developed postural control to maintain technical performance and reduce injury risk. Although fatigue has been reported to impair balance performance, previous studies have primarily induced fatigue using non-specific laboratory protocols that do not adequately reflect the physiological and neuromuscular demands of taekwondo competition. Consequently, the effects of taekwondo-specific fatigue on static and dynamic balance performance remain insufficiently understood. The primary objective of this study will be to investigate the effects of a taekwondo match-simulated fatigue protocol on static and dynamic balance performance in female taekwondo athletes. Eighteen competitive female taekwondo athletes will participate in this single-group repeated-measures study. Following a familiarization session, participants will complete a standardized taekwondo match-simulated fatigue protocol consisting of three 2-minute rounds separated by 1-minute passive recovery periods, replicating the official Olympic competition format. Static and dynamic balance performance will be assessed before and immediately after the fatigue protocol using the Biodex Balance System (Biodex Medical Systems Inc., Shirley, NY, USA). Balance performance will be evaluated under static and dynamic testing conditions, and the Overall Stability Index, Anteroposterior Stability Index, and Mediolateral Stability Index will be recorded. The findings of this study are expected to improve understanding of the acute effects of sport-specific fatigue on postural control in female taekwondo athletes and may contribute to the development of evidence-based training and injury prevention strategies.",[182,183,184,76,185,30],"Taekwondo Match-simulated Fatigue","Static Balance","Dinamic Balance","Postural Balance","2026-08-06",{"date":109,"type":41},{"date":189,"type":23},"2026-08",{"date":191,"type":23},"2026-11",{"name":193,"class":48},"Berkay Löklüoğlu",{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":58,"sex":18,"minAge":60,"maxAge":125,"enrollmentInfo":200,"targetDuration":4,"studyType":24,"phases":202,"briefSummary":203,"conditions":204,"keywords":208,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":49},"100650853","investigation-on-the-chronic-effects-of-nepalese-pepper-zanthoxylum-armatum-dc-on-cognitive-function-mood-and-gaming-performance-in-young-healthy-action-video-gamers-100650853","NCT07752329","Investigation on the Chronic Effects of Nepalese Pepper (Zanthoxylum Armatum DC) on Cognitive Function, Mood and Gaming Performance in Young, Healthy, Action Video Gamers","Inclusion Criteria:\n\n* Aged 16 to 39 years inclusive\n* Males and females\n* Self-report of good health\n* Usually a regular (at least 5 hours per week on average) player of action video games, including but not limited to First-Person Shooters (FPS) and Massive Online Battle Arenas (MOBA), (prospective participants will be asked to contact the researchers to discuss their gaming habits if uncertain that they meet the criteria).\n\nExclusion Criteria:\n\n* Have any pre-existing medical condition\u002Fillness which will impact taking part in the study (i.e. participants may be allowed to progress to screening if they have a condition\u002Fillness which would not interact with the active treatments or impede performance).\n* Are currently taking prescription medications. NOTE: the explicit exceptions to this are contraceptive treatments for female participants, and those taken 'as needed' in the treatment of asthma and hay fever. There may be other instances of medication use which, where no interaction with the active treatments is likely, and which would not be expected to have any impact on brain function, participants may be able to progress to screening.\n* Have high blood pressure (systolic over 139 mm Hg or diastolic over 89 mm Hg); or have low blood pressure (systolic below 90 mm Hg or diastolic below 60 mm Hg)\n* Have a Body Mass Index (BMI) outside of the range 18.5-35 kg\u002Fm2\n* Are pregnant, seeking to become pregnant or lactating\n* Have learning and\u002For behavioural diagnoses such as dyslexia or ADHD\n* Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness)\n* Smoke tobacco or vape nicotine or use nicotine replacement products\n* Excessive caffeine intake (\\> 500 mg per day). If participants consume energy drinks they will be asked to refrain from this for 24 hours prior to attending testing.\n* Have relevant food intolerances\u002Fsensitivities.\n* Have taken antibiotics within the past 4 weeks\n* Have taken dietary supplements e.g. Vitamins, omega 3 fish oils etc. in the last 4 weeks (Note: participation is possible following a 4-week supplement washout prior to participating and for the duration of the study on the proviso that the supplements taken are out of choice and not medically prescribed or advised)\n* Have any health condition that would prevent fulfilment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken)\n* Are unable to complete all of the study assessments\n* Are currently participating in other clinical or nutrition intervention studies, or have done so in the past 4 weeks\n* Has been diagnosed with\u002F undergoing treatment for alcohol or drug abuse in the last 12 months\n* Have been diagnosed with\u002F undergoing treatment for a psychiatric disorder in the last 12 months\n* Suffers from frequent migraines that require medication (more than or equal to 1 per month)\n* Sleep disorders or are taking sleep aid medication\n* Any known active infections\n* Are non-compliant with regards treatment consumption",{"count":201,"type":23},70,[26],"The goal of this clinical trial is to learn if daily supplementation with a Nepalese Pepper Extract (Zanthoxylum Armatum, ZA) can improve cognitive performance and gaming performance in action video gamers aged 16 to 39, when taken over an extended period. The main questions it aims to answer are:\n\nDoes chronic (42-day) daily ZA supplementation improve speed of cognitive performance and reduce subjective mental fatigue? Do these effects translate into objective and self-reported improvements in gaming performance? Are there additional acute (within-session) effects at the end of a chronic supplementation period, on top of any chronic effect?\n\nResearchers will compare 275mg daily ZA supplementation to placebo to see if chronic ZA produces better cognitive performance and lower fatigue than placebo. Participants will:\n\nComplete a screening call and a training visit on the computerised cognitive tasks and gaming tasks Take a daily capsule (either ZA or placebo, depending on treatment order) each morning with food for 42 days, then switch to the other treatment for a further 42 days after a 2-week washout Attend four testing visits at the research centre: a baseline and an endpoint visit for each 42-day treatment period Avoid alcohol and energy drinks for 24 hours before each testing visit, and caffeine from waking Complete cognitive tests before dosing and 1 hour after dosing at each testing visit Complete mood and sleep questionnaires Wear a heart rate monitor at rest on arrival at each visit Complete gaming-specific tasks (aim training, MOBA character control, multi-tasking, finger tapping, Fitts' Law, multiple object tracking, collision prediction) Play their action video game of choice at home throughout each 42-day period and complete performance questionnaires",[205,206,207,30],"Cognition","Mood","Gaming Performance",[205,206,209,210,211,212,213,214,30,215],"Gaming","Performance","Esports","Nepalese Pepper","Timut Pepper","Zanthoxylum Armatum","Chronic Supplementation","2026-08-03",{"date":161,"type":41},{"date":219,"type":23},"2026-08-20",{"date":221,"type":23},"2027-09",{"name":223,"class":48},"Northumbria University",{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":12,"sex":59,"minAge":19,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":24,"phases":235,"briefSummary":236,"conditions":237,"keywords":241,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":49},"100650401","posh-ex-physiotherapist-led-telerehabilitation-exercise-programme-for-postpartum-sexual-health-100650401","NCT07747285","POSH-Ex: Physiotherapist-Led Telerehabilitation Exercise Programme for Postpartum Sexual Health","POSH-Ex: Randomized Controlled Trial Evaluating a Standardized Physiotherapist-Led Telerehabilitation Programme for Postpartum Sexual Health","POSH-Ex","Inclusion Criteria:\n\n* Women aged 18 to 45 years.\n* Between 10 and 12 weeks postpartum at the time of enrolment.\n* Singleton live birth.\n* Ability to understand and communicate in the Croatian language.\n* Ability to participate safely in moderate-intensity exercise.\n* Access to a computer, tablet, or smartphone with a stable internet connection for participation in online exercise sessions.\n* Willingness to comply with the study protocol and attend supervised exercise sessions.\n* Provision of written informed consent.\n\nExclusion Criteria:\n\n* • Medical contraindications to exercise according to current clinical recommendations.\n\n  * Pregnancy during the study period.\n  * Severe musculoskeletal, neurological, cardiovascular, or other medical conditions preventing safe participation in exercise.\n  * Current participation in another structured postpartum rehabilitation or exercise programme.\n  * Severe psychiatric disorder requiring immediate specialist treatment.\n  * Positive response to Item 10 of the Edinburgh Postnatal Depression Scale indicating current thoughts of self-harm. Such participants will be referred for appropriate clinical assessment before potential study participation.\n  * Inability to complete study questionnaires or follow study procedures.","45 Years",{"count":234,"type":23},84,[26],"Postpartum women frequently experience impairments in sexual function, pelvic floor dysfunction, fatigue, and depressive symptoms, all of which may adversely affect their quality of life during the postpartum period. Although pelvic floor muscle training is recommended as part of postpartum rehabilitation, evidence regarding comprehensive physiotherapist-led exercise programmes specifically targeting postpartum sexual health remains limited. Furthermore, no standardized telerehabilitation programme has yet been evaluated using a randomized controlled trial design.\n\nThe aim of this randomized controlled trial is to evaluate the effectiveness of the POSH-Ex (Postpartum Sexual Health Exercise) programme, a standardized 12-week physiotherapist-led telerehabilitation intervention designed to improve female sexual function and overall postpartum health after childbirth. Secondary objectives are to evaluate its effects on pelvic floor muscle strength, physical activity, fatigue, depressive symptoms, health-related quality of life, and body composition.\n\nA total of 84 postpartum women will be randomly allocated in a 1:1 ratio to either the intervention group or the control group. Participants in the intervention group will complete supervised online exercise sessions twice weekly for 12 weeks, while participants in the control group will receive usual postpartum care. Outcome assessments will be performed at baseline and immediately after completion of the intervention.\n\nThe primary outcome is female sexual function assessed using the Female Sexual Function Index (FSFI). Secondary outcomes include pelvic floor muscle strength, physical activity, fatigue, depressive symptoms, health-related quality of life, and body composition. The findings are expected to provide high-quality evidence regarding the effectiveness of a standardized telerehabilitation programme for postpartum rehabilitation and may contribute to the development of evidence-based postpartum rehabilitation programmes and future clinical practice guidelines.",[238,239,30,240],"Postpartum Sexual Dysfunction","Postpartum Depression","Physical Activity",[242,243,244,245,246,247,66,230],"postpartum","Postpartum rehabilitation","Postpartum sexual health","Female sexual function","Pelvic floor muscle training","Telerehabilitation","2026-07-30",{"date":250,"type":41},"2026-08-05",{"date":252,"type":23},"2026-09-01",{"date":254,"type":23},"2027-09-30",{"name":256,"class":48},"University Medical Centre Ljubljana",{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":58,"sex":18,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":24,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":275,"leadSponsor":277,"locationsCount":49},"100650114","radicle-energy-dnb-a-study-assessing-the-impact-of-health-and-wellness-products-on-fatigue-and-related-health-outcomes-100650114","NCT07745010","Radicle Energy™ DNB: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes","Radicle Energy™ DNB: A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Health Outcomes","\\- Inclusion\n\nParticipants must meet all the following criteria:\n\n* Adults, at least 40 years of age at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n  * Assigned sex at birth will determine sex-specific recruitment and PROs (male vs female) employed, when needed\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study\n\n  * Exclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n\n  * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of the primary ingredient(s) and\u002For similar product(s) to the active study product(s) that may limit the effects of the study products and\u002For pose a safety risk\n* Lack of reliable daily access to the internet","40 Years","105 Years",{"count":267,"type":23},1320,[26],"Radicle Energy™ DNB: A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on fatigue and related health outcomes",[30],"2026-07-29",{"date":273,"type":41},"2026-08-04",{"date":43,"type":23},{"date":276,"type":23},"2027-08-13",{"name":278,"class":117},"Radicle Science",{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":287,"minAge":19,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":24,"phases":290,"briefSummary":291,"conditions":292,"keywords":297,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":49},"100649459","emindexcare-for-prostate-cancer-patients-undergoing-active-treatment-100649459","NCT07735273","eMindExCare for Prostate Cancer Patients Undergoing Active Treatment","Effects of Integrated Mindfulness and Exercise eHealth Intervention (eMindExCare) on Sleep, Fatigue, and Physical Activity Among Prostate Cancer Patients Undergoing Active Treatment: A Feasibility Trial","eMindExCare","Inclusion Criteria:\n\n1. Diagnosed with prostate cancer, stage I, II, or III.\n2. Aged older than 18 years.\n3. Undergoing active treatment, including chemotherapy, radiotherapy, or hormone therapy, at Prince of Wales Hospital.\n4. Able to communicate and read Chinese.\n5. Has access to the Internet and a computer or tablet.\n6. Demonstrates clinically impaired sleep quality or insufficient physical activity as measured by ActiGraph. Clinically impaired sleep quality may include study-defined sleep disturbance criteria such as total sleep time less than 6.5 hours, sleep onset latency greater than 30 minutes, awakenings lasting greater than 5 minutes, or wake after sleep onset greater than 30 minutes.\n\nExclusion Criteria:\n\n1. Diagnosed with more than one primary cancer.\n2. Has metastatic disease.\n3. Has participated in a mindfulness programme.\n4. Is sufficiently physically active at the time of recruitment.\n5. Has a mental condition, World Health Organization\u002FEastern Cooperative Oncology Group performance status greater than 2, a physical disability that prevents participation in the intervention, or any other health problem that rules out regular physical activity as determined by the treating physician.","MALE",{"count":289,"type":23},60,[26],"This feasibility randomized controlled trial will assess the acceptability, feasibility, and preliminary effects of an integrated mindfulness and exercise eHealth intervention, eMindExCare, among prostate cancer patients undergoing active treatment in Hong Kong. Participants will be randomized in a 1:1 ratio to either an 8-week eMindExCare intervention or an enhanced health education attention-control programme. eMindExCare integrates culturally adapted Cantonese mindfulness practices with home-based aerobic and resistance exercise delivered through Zoom, supported by home practice, exercise logs, and weekly reminders. The enhanced health education control programme will match the intervention group in contact time and engagement but will not include progressive aerobic training, resistance-band prescription, stationary bike provision, or a structured mindfulness curriculum. Feasibility and acceptability outcomes will include eligibility, consent, randomization, attendance, retention, questionnaire completion, missing data, and adverse events. Preliminary outcomes will include sleep quality, fatigue, pain, physical activity, mindfulness, motivation for exercise, and quality of life assessed at baseline, immediately post-intervention at week 8, and 3 months post-intervention.",[293,294,30,295,296],"Prostate Cancer","Sleep Disturbance","Physical Inactivity","Pain",[293,298,285,299,300,301,302,303,304,108,305,306,307,308,309],"prostate neoplasms","mindfulness","exercise","physical activity","eHealth","sleep quality","sleep disturbance","pain","quality of life","feasibility trial","pilot randomized controlled trial","Hong Kong","2026-07-28",{"date":271,"type":41},{"date":313,"type":23},"2026-10-01",{"date":315,"type":23},"2028-09-30",{"name":317,"class":48},"The University of Hong Kong",{"id":319,"slug":320,"hasResults":12,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":58,"sex":59,"minAge":325,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":24,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":332,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":4},"100649369","radicle-womens-health-dns-a-study-assessing-the-impact-of-health-and-wellness-products-on-fatigue-and-related-womens-health-outcomes-100649369","NCT07735247","Radicle Women's Health DNS™: A Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Women's Health Outcomes","Radicle Women's Health DNS™: A Randomized, Double-Blind, Placebo-Controlled Direct-to-Consumer Study Assessing the Impact of Health and Wellness Products on Fatigue and Related Women's Health Outcomes","3.1 Inclusion\n\nParticipants must meet all the following criteria:\n\n* Adult females, 21-60 years of age (inclusive) at the time of electronic consent, inclusive of all ethnicities, races, and gender identities\n\n  * Assigned sex at birth will determine sex-specific recruitment and PROs\n* Resides in the United States\n* Has the opportunity for at least 30% improvement in their primary health outcome\n* Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study\n\n3.2 Exclusion\n\nIndividuals who report any of the following during screening may be excluded from participation:\n\n* Report being pregnant, trying to become pregnant, or breastfeeding\n* Unable to provide a valid US shipping address and mobile phone number\n* Reports current enrollment in another clinical trial\n* Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)\n* Unable to read and understand English at a 7th grade level\n* Reports a current and\u002For recent (up to 3 months ago) major illness and\u002For surgery that poses a known, significant safety risk.\n* Reports a diagnosis of cardiac dysfunction, liver or kidney disease that presents a known contraindication and\u002For a significant safety risk with any of the study product ingredients.\n\n  * NYHA Class III or IV congestive heart failure, atrial fibrillation, uncontrolled arrhythmias, cirrhosis, end-stage liver disease, stage 3b or 4 chronic kidney disease, or kidney failure\n* Reports taking medications that have a well-established moderate or severe interaction, posing a substantial safety risk with any of the study product ingredients.\n\n  * Anticoagulants, antihypertensives, anxiolytics, antidepressants, chemotherapy, immunotherapy, sedative hypnotics, seizure medications, medications that warn against grapefruit consumption, corticosteroids at doses greater than 5 mg per day, diabetic medications, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, MAOIs, or thyroid products\n* Reports current use of supplements with rhodiola root or maca root extract\n* Lack of reliable daily access to the internet","21 Years","60 Years",{"count":328,"type":23},550,[26],"Radicle Women's Health DNSTM: A randomized, double-blind, placebo-controlled direct-to-consumer study assessing the impact of health and wellness products on fatigue and related women's health outcomes",[30],{"date":271,"type":41},{"date":334,"type":23},"2026-07-14",{"date":336,"type":23},"2027-07-14",{"name":278,"class":117},{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":24,"phases":348,"briefSummary":349,"conditions":350,"keywords":353,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":49},"100464865","phase-1-modafinil-to-improve-fatiguability-100464865","NCT05333250","Modafinil to Improve Fatiguability","Modafinil to Improve Fatiguability (MODIFY): Modafinil vs. Placebo Vanguard RCT","MODIFY","Inclusion Criteria:\n\n1. 18 years of age or older with stage III or IV cancer diagnosis\n2. Estimated prognosis ≥ 3 months\n3. Eastern Cooperative Oncology Group (ECOG) Score 0-2\n4. Experiencing cancer-related fatigue, defined as a score of 4 or greater on the Fatigue item of the Edmonton Symptom Assessment System-revised-constipation\u002Fsleep (ESAS-r-cs)\n5. Ability to understand and communicate in English\n6. Ability to give first-person informed consent\n\nExclusion Criteria:\n\n* Currently receiving or have received cytotoxic chemotherapy in the last 6 weeks\n* Allergy to modafinil or placebo contents\n* Dose change of prednisone or dexamethasone in the past 7 days or planned dose change during study period\n* Blood transfusion in the last 2 weeks\n* Hemoglobin lower than 80 g\u002FL measured in the last 4 weeks\n* TSH above normal range in the last 4 weeks\n* Severe liver dysfunction (total bilirubin \\>3x upper limit of normal, or aspartate aminotransferase or alanine aminotransferase \\>5x upper limit of normal)\n* Known brain metastasis or primary brain tumor\n* Documented dementia diagnosis\n* Documented major psychiatric illness including major depressive episode, bipolar disorder, schizophrenia\n* Uncontrolled hypertension as defined by a blood pressure greater than 140\u002F90mmHg\n* Unstable angina\n* Recent (\\\u003C6 months previous) myocardial infarction\n* Evidence of left ventricular hypertrophy or ischemia on ECG\n* Arrythmia (e.g., atrial fibrillation)\n* Coronary artery disease with Canadian Cardiovascular Society Symptoms Class \\>1\n* Taking high dose selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants\n* Taking any benzodiazepine at any dose\n* Taking any amphetamine at any dose\n* Taking any monoamine oxidase inhibitor (MAOI) at any dose\n* Taking any azole anti-fungal medication (e.g., fluconazole, itraconazole, or ketoconazole)\n* Taking any of the following medications at any dose:\n\n  1. Methylphenidate\n  2. Cyclosporine\n  3. Propranolol\n  4. Phenytoin\n  5. S-mephenytoin\n  6. Warfarin\n  7. Triazolam\n  8. Ethinyl estradiol\n  9. Clomipramine\n  10. Midodrine\n  11. Antipyrine\n* Inability to ingest oral capsule\n* Pregnancy or lactation, or trying to conceive\n* Any other history, condition, therapy, or uncontrolled intercurrent illness which could, in the opinion of the Qualified Medical Investigator, affect compliance with study requirements or which would make the participant unsuitable for this study.\n* Simultaneous participation in another interventional clinical study (e.g., Phase 1-3 clinical studies) or treatment with any investigational medicinal product within 30 days prior to screening visit that could, in the judgment of the Qualified Medical Investigator, affect the patient's participation in or outcome of this clinical trial.",{"count":347,"type":23},40,[153,154],"Cancer-related fatigue (CRF) and cancer-related cognitive impairment (CRCI) are among the most commonly reported disabling symptoms experienced by patients with advanced cancer. However, there are currently limited evidence-based pharmacologic interventions available. The investigators will conduct a Vanguard Randomized Clinical Trial (RCT) to estimate the effect of modafinil in managing CRF and CRCI, and to test the feasibility of carrying out the study.",[351,352,30],"Cancer-related Cognitive Difficulties","Cancer-related Problem\u002FCondition",[131,30,354,355],"Cognitive Impairment","Modafinil","2026-07-24",{"date":358,"type":41},"2026-07-27",{"date":360,"type":41},"2026-03-16",{"date":362,"type":23},"2028-03",{"name":364,"class":48},"Ottawa Hospital Research Institute",{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":374,"phases":4,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":385},"100564838","patient-descriptors-of-cancer-related-fatigue-a-mixed-methods-pilot-study-of-cancer-survivors-100564838","NCT06634381","Patient Descriptors Of Cancer-Related Fatigue: A Mixed Methods Pilot Study Of Cancer Survivors","VAP","Inclusion Criteria:\n\n* Ability to comply with study procedures for the duration of the study\n\nSurvivors:\n\n* Written informed consent and HIPAA authorization for release of personal information\n* Ability to read\u002Fwrite, understand and converse in English without the need for an interpreter\n* Men and women aged ≥ 18 years at the time of consent\n* History of at least one visit for the purpose of monitoring long term care post curative treatment at LCH and\u002For the Charlotte or Winston-Salem campuses of AHWFBCCC\n* Completed curative treatment \\> 6 months ago for any cancer type, with no detectable evidence of cancer\n* Self-reported tiredness, exhaustion, or weakness (i.e. fatigue) score of ≥ 4 on the Numerical Rating Scale\n* Adjuvant endocrine therapy to reduce the risk of cancer returning is acceptable (i.e. tamoxifen or aromatase inhibitors).\n\nClinicians:\n\n\\- Currently see oncology patients (any cancer type) for survivorship care at LCH and\u002For the Charlotte or Winston-Salem campuses of AHWFBCCC\n\nExclusion Criteria:\n\nSurvivors:\n\n* Continuing maintenance therapy or other cancer-related treatment (i.e. immunotherapy)\n* History of or current untreated Major Depressive Disorders or untreated severe depression\n* Hemoglobin \\\u003C11g\u002FdL at last CBC SOC lab collection\n* History\u002Fdiagnosis of dementia\n* Factors or conditions, for which participation may (1) not be in the best interest or (2) interfere with study assessment results (e.g. medical comorbidities, primary brain tumor\u002Fmetastases)\n* No access to internet\u002FWi-Fi\n\nClinicians:\n\n\\- None",{"count":373,"type":23},80,"OBSERVATIONAL","The purpose of this research study is to better understand how cancer-related fatigue affects patients and how it's discussed with providers. This information will be used to develop an educational resource (visual aid poster) that could help individuals and their providers talk about cancer-related fatigue and which may help individuals better manage this symptom.",[131,30],"2026-07-22",{"date":356,"type":41},{"date":380,"type":41},"2025-03-12",{"date":382,"type":23},"2028-06",{"name":384,"class":48},"Wake Forest University Health Sciences",3,{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":396,"briefSummary":397,"conditions":398,"keywords":402,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":4},"100647436","transcranial-direct-current-stimulation-for-long-covid-brain-fog-and-fatigue-100647436","NCT07709234","Transcranial Direct Current Stimulation for Long COVID Brain Fog and Fatigue","The Impact of Transcranial Direct Current Stimulation on Quality of Life, Brain Fog, and Fatigue in Patients With Long COVID: Study Protocol of the NEUROSTIM-LC Study","NEUROSTIM-LC","Inclusion Criteria:\n\n* Adults aged between 18 and 70 years.\n* Diagnosis of long COVID according to World Health Organization criteria, defined as symptoms persisting for at least three months after acute SARS-CoV-2 infection and lasting for a minimum of two months without an alternative explanation.\n* Presence of persistent fatigue and\u002For cognitive impairment, commonly described as brain fog, attributed to long COVID and confirmed at screening.\n* Stable clinical condition allowing participation in the intervention and assessment procedures.\n* Ability to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* Contraindications to transcranial direct current stimulation, including the presence of implanted electronic devices such as pacemakers or neurostimulators, intracranial metallic implants, or history of epilepsy or seizures.\n* History of neurological disorders that may affect cognitive function, including stroke, Parkinson's disease, or neurodegenerative disorders.\n* Pre-existing conditions associated with chronic fatigue or cognitive impairment prior to SARS-CoV-2 infection, such as fibromyalgia, chronic fatigue syndrome, or multiple sclerosis.\n* Severe psychiatric disorders, including psychosis or severe depression.\n* Substance abuse, including alcohol or drugs.\n* Current oncological treatment with chemotherapy or radiotherapy.\n* Pregnancy.\n* Any medical condition that, in the opinion of the investigators, may interfere with participation or with the interpretation of the results.","70 Years",{"count":178,"type":23},[26],"Long COVID can cause persistent symptoms such as fatigue, cognitive difficulties commonly described as brain fog, reduced exercise tolerance, and impaired quality of life. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that may help modulate brain activity in regions involved in cognition, fatigue, and executive function.\n\nThe NEUROSTIM-LC study will evaluate the feasibility and potential effects of repeated tDCS sessions in adults with long COVID presenting fatigue and\u002For brain fog. Participants will receive 30 sessions of tDCS applied over the left dorsolateral prefrontal cortex. Assessments will be performed before and after the intervention to evaluate changes in quality of life, fatigue, cognitive function, brain metabolism, physical performance, autonomic function, sleep quality, psychological symptoms, respiratory function, and blood biomarkers.",[399,400,30,401],"Long COVID","Post-COVID Conditions","Cognitive Dysfunction",[403,404,405,399,406,407,408,409,410,411],"Transcranial direct current stimulation","tDCS","Brain fog","Chronic Fatigue","Quality of life","Cognitive impairment","Heart rate variability","PET-CT","Neuromodulation","2026-07-19",{"date":377,"type":41},{"date":415,"type":23},"2026-09-15",{"date":417,"type":23},"2028-03-01",{"name":419,"class":48},"University of Las Palmas de Gran Canaria",{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":428,"targetDuration":4,"studyType":24,"phases":429,"briefSummary":430,"conditions":431,"keywords":434,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":440,"leadSponsor":442,"locationsCount":49},"100648073","home-based-high-intensity-interval-training-in-systemic-lupus-erythematosus-100648073","NCT07716462","Home-Based High-Intensity Interval Training in Systemic Lupus Erythematosus","Exercise and Muscle Biology in Systemic Lupus Erythematosus","MIGHT-SLE","Inclusion Criteria:\n\n* Age 18 to 65 years.\n* Diagnosis of systemic lupus erythematosus according to the 2019 European Alliance of Associations for Rheumatology\u002FAmerican College of Rheumatology classification criteria.\n* Stable, non-organ-threatening systemic lupus erythematosus, defined as a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 6 or less at screening, with no active renal or central nervous system involvement.\n* Stable background lupus therapy, defined as no initiation of a new disease-modifying antirheumatic drug or biologic therapy and no change in the dose of immunosuppressive therapy within 8 weeks before enrollment.\n* Persistent fatigue and\u002For muscle pain, with a PROMIS Fatigue T-score of 55 or greater.\n* Stable prednisone dose, or equivalent glucocorticoid dose, of 5 mg per day or less for at least 12 weeks before enrollment.\n* Able to safely participate in a moderate-intensity exercise program.\n* Able and willing to provide informed consent.\n* Able and willing to comply with the home-based exercise protocol and study procedures.\n\nExclusion Criteria:\n\n* Prednisone dose greater than 5 mg per day, or receipt of a glucocorticoid burst within 8 weeks before enrollment.\n* Pregnancy.\n* Severe anemia, defined as hemoglobin less than 10 g\u002FdL.\n* Uncontrolled hypothyroidism.\n* Severe systemic lupus erythematosus disease activity, defined as a SLEDAI-2K score greater than 8.\n* End-stage kidney disease requiring renal replacement therapy or estimated glomerular filtration rate less than 30 mL\u002Fmin\u002F1.73 m².\n* Uncontrolled hypertension, defined as blood pressure greater than 160\u002F100 mmHg.\n* Decompensated heart failure.\n* Unstable pulmonary disease.\n* Neurologic condition that limits exercise performance.\n* Uncontrolled diabetes mellitus.\n* Severe osteoarthritis that limits safe participation in the exercise intervention.\n* Overlap autoimmune disease, including inflammatory myopathy, mixed connective tissue disease, or systemic sclerosis.\n* History of solid-organ or bone marrow transplantation.\n* Any contraindication to magnetic resonance imaging.\n* Inability to fit safely on the magnetic resonance imaging scanner bed.\n* Myocardial infarction or cerebrovascular event within the previous 3 months.\n* Serious hemorrhage, including cerebral hemorrhage, within the previous 12 months.\n* Acute infectious illness within 1 month before enrollment.\n* Inability to provide informed consent.\n* Inability to adhere to the home-based exercise protocol.\n* Current participation in a structured exercise program.",{"count":178,"type":23},[26],"Systemic lupus erythematosus, or SLE, is a chronic autoimmune disease that can cause persistent fatigue, muscle pain, reduced physical function, and impaired quality of life, even when the disease is otherwise clinically stable. The biological mechanisms contributing to these symptoms are not fully understood. Abnormal energy production within skeletal muscle and increased fat accumulation within the muscle may contribute to fatigue and reduced physical performance in people with SLE.\n\nThis pilot study will evaluate the effects of a 16-week personalized, home-based exercise program in 20 adults with stable SLE and clinically significant fatigue. The program will include three exercise sessions per week: bodyweight high-intensity interval training, strength training, and walking-based interval training. Sessions will be adapted to each participant's fitness, mobility, symptoms, and exercise tolerance. Some sessions will be supervised remotely by video, while others will be completed independently using personalized recorded instructions.\n\nParticipants will undergo assessments before and after the 16-week program. These assessments will examine skeletal muscle mitochondrial function, fat accumulation within the thigh muscles, physical performance, fatigue, quality of life, and blood-based markers of mitochondrial function and inflammation.\n\nThe study will help determine whether a personalized home-based exercise program can improve muscle health and physical function in people with SLE and will provide information needed to design larger future studies.",[432,30,433],"Systemic Lupus Erthematosus","Exercise Training",[435,30,66],"SLE","2026-07-16",{"date":438,"type":41},"2026-07-21",{"date":313,"type":23},{"date":441,"type":23},"2027-12",{"name":443,"class":48},"University of Alabama at Birmingham",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":58,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":374,"phases":4,"briefSummary":454,"conditions":455,"keywords":457,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":473},"100573223","capturing-key-mg-symptoms-using-smartphone-recordings-100573223","NCT06743490","Capturing Key MG-symptoms Using Smartphone Recordings.","Capturing Key Symptoms Using Smartphone Recordings in Patients With Myasthenia Gravis (CAPTURE-MG)","CAPTURE - MG","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ability to understand the requirements of the study and provide written informed consent.\n\nInclusion Criteria for MG participants only:\n\n1. A clinical diagnosis of myasthenia gravis (ocular or generalized) as defined by the Dutch national guideline (category \"definite\" or \"probable\" MG).\n2. MGFA Clinical Classification of disease severity I-IV.\n3. Subjects have at least one of the symptoms of interest (namely dysarthria, dysphonia, proximal arm fatigue and\u002For ptosis).\n\nInclusion Criteria for non-MG participants only\n\n1. Subjects are not diagnosed with and have no clinical suspicion of MG.\n2. Subjects do not have a medical history of any of the symptoms of interest (namely dysarthria, dysphonia, proximal arm fatigue and\u002For ptosis).\n\nExclusion Criteria:\n\n1. Not willing to be audio-recorded for the study assessments.\n2. Not willing to be video-recorded for the study assessments.\n3. Subjects currently taking part in a clinical trial of an Investigational Medicinal Product.\n4. Subjects who have used an immediate release pyridostigmine-based medication in the 12 hours prior to their participation and participants on prolonged release pyridostigmine.\n5. Subjects have cognitive or physical limitations that, in the opinion of the investigator, limits the subject's ability to complete study procedures\u002F\n\nExclusion Criteria for MG participants only:\n\n1. Subjects with an upper-limb amputation or who are non-verbal.\n2. Subjects with a diagnosed neurological disease resulting in muscle weakness, other than MG.\n\nExclusion Criteria for non-MG participants only:\n\n1\\. Limitation of upper limb mobility or speech impairment of any cause.",{"count":453,"type":23},225,"This study will make use of a cross-sectional design of MG patients and non-MG participants to quantitatively assess key MG symptoms, and to explore the applicability of machine learning algorithms to their measurement.",[456,30],"Myasthenia Gravis",[456,30,458,459,460,461,462,463],"Digital features","Machine Learning Algorithms","Dysarthria","Dysphonia","Proximal arm fatigue","Ptosis","2026-07-06",{"date":466,"type":41},"2026-07-08",{"date":468,"type":41},"2025-03-18",{"date":470,"type":23},"2026-09-30",{"name":472,"class":48},"Leiden University Medical Center",2,{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":58,"sex":18,"minAge":19,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":374,"phases":4,"briefSummary":484,"conditions":485,"keywords":486,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":49},"100646812","alterations-in-spiking-following-muscle-fatigue-in-volleyball-players-100646812","NCT07687550","Alterations in Spiking Following Muscle Fatigue in Volleyball Players","Alterations in Spiking Kinematic, Muscle Activation, and Subacromial Structures Following Muscle Fatigue in Volleyball Players","Inclusion Criteria:\n\n* Between 18 and 35 years old\n* At least 2 consecutive years of volleyball experience\n* Involved in volleyball practice or game for at least 4 hours per week\n* Able to perform a cross-body spike with 3-step\n\nExclusion Criteria:\n\n* A history of major shoulder or spinal injury or surgery\n* Experiencing shoulder pain (VAS ≥ 3\u002F10) in the last 6 months","35 Years",{"count":483,"type":23},35,"This study aims (1)to investigate the effects of repetitive functional overhead movements targeting shoulder and scapular muscles on glenohumeral and scapular kinematics and muscle activation during the arm cocking and acceleration of spiking, and changes in subacromial structures in healthy recreational volleyball players; (2) to compare these fatigue-related changes between athletes with good and poor shoulder motor control.",[30],[30,487,488],"Athlete","Volleyball","2026-07-01",{"date":491,"type":41},"2026-07-07",{"date":493,"type":23},"2026-07",{"date":495,"type":23},"2027-01",{"name":497,"class":48},"National Yang Ming Chiao Tung University",{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":59,"minAge":19,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":24,"phases":508,"briefSummary":509,"conditions":510,"keywords":516,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":522,"leadSponsor":524,"locationsCount":49},"100645034","effect-of-virtual-reality-guided-imagery-on-pain-anxiety-and-fatigue-in-cancer-patients-undergoing-chemotherapy-100645034","NCT07677436","Effect of Virtual Reality-Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy","Effect of Virtual Reality Guided Imagery on Pain, Anxiety, and Fatigue in Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial","VRGI-Chemo Tri","Inclusion Criteria:\n\n* Female patients aged 18 years or older.\n* Histologically confirmed breast cancer.\n* Stage I, II, or III breast cancer.\n* Underwent surgery as the initial treatment and are scheduled to receive the first cycle of adjuvant chemotherapy, with or without biologic therapy (e.g., AC or TC regimens).\n* Able to read, write, and communicate.\n* Able and willing to use a virtual reality headset.\n* Able to provide written informed consent.\n\nExclusion Criteria:\n\n* Visual or hearing impairment that prevents the use of virtual reality.\n* Serious neurological or psychiatric disorders.\n* Current participation in other non-pharmacological interventions (e.g., meditation or relaxation therapy) that could influence the study outcomes.\n* Previous experience with virtual reality-guided imagery.\n* Use of analgesics, anxiolytics, or other medications during the intervention that may affect the study outcomes.",{"count":507,"type":23},108,[26],"This randomized controlled trial aims to evaluate the effectiveness of virtual reality-guided imagery in reducing pain, anxiety, and fatigue among female breast cancer patients undergoing adjuvant chemotherapy. Participants will be randomly assigned to either an intervention group receiving virtual reality-guided imagery in addition to routine care, or a control group receiving routine care",[511,512,513,514,296,515,30],"Virtual Reality","Guided Imagery","Breast Cancer","Chemotherapy","Anxiety",[517],"Virtual Reality, Guided Imagery , Breast Cancer, Chemotherapy , Pain, Anxiety , Fatigue","2026-06-27",{"date":520,"type":41},"2026-06-30",{"date":489,"type":23},{"date":523,"type":23},"2027-03",{"name":525,"class":48},"Thoalfokar Mohammed Al-Obaidi",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":58,"sex":18,"minAge":19,"maxAge":232,"enrollmentInfo":533,"targetDuration":4,"studyType":24,"phases":535,"briefSummary":536,"conditions":537,"keywords":542,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":550,"locationsCount":49},"100638363","photobiomodulation-effects-on-fatigue-and-muscle-damage-induced-by-nmes-100638363","NCT07602933","Photobiomodulation Effects on Fatigue and Muscle Damage Induced by NMES","Effects of Photobiomodulation on Fatigue and Muscle Damage Induced by Neuromuscular Electrical Stimulation in Healthy Individuals: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Healthy male and female volunteers.\n* Age between 18 and 45 years.\n* Practice physical activity regularly\n* No history of musculoskeletal injuries in the lower limbs in the last 6 months\n* Ability to tolerate NMES\n\nExclusion Criteria:\n\n* Have sensory intolerable changes due to NMES\n* Consumed coffee or another stimulant in the last 12 hours\n* Have a body mass index (BMI) greater than 30 kg\u002Fm2 (grade I obesity)\n* Present any contraindication for the performance of maximum effort\n* Abnormal increase in blood pressure after maximal exertion",{"count":534,"type":23},36,[26],"Neuromuscular electrical stimulation (NMES) is widely used to improve muscle strength and mitigate atrophy. However, its clinical efficacy is often limited by early neuromuscular fatigue, muscle damage, and discomfort, which reduce patient tolerance and contraction time. Photobiomodulation (PBM) has emerged as a potential therapy to enhance muscle performance and accelerate recovery by minimizing fatigue and damage. Despite its potential, few studies have investigated the effects of PBM applied specifically before an NMES-evoked fatigue protocol. This randomized, double-blind, placebo-controlled trial aims to evaluate the acute effects of PBM on neuromuscular fatigue, muscle damage, and functional outcomes in healthy young subjects. Participants will receive either active PBM (cluster probe: 5 lasers 810nm\u002F200mW; 4 LEDs 660nm\u002F10mW; Total Energy: 249.6 J per limb) or sham treatment 5 minutes before a fatiguing NMES protocol (80 contractions at 20% MVIC, 80 Hz, 1ms pulse width) applied to the quadriceps muscle. Assessments will be performed at baseline, immediately post-intervention, and at 24h, 48h, and 72h post-intervention. Primary outcomes include maximum and evoked isometric strength, mechanical work, and electrical muscle activity. Secondary outcomes include muscle damage (ultrasound echo-intensity), delayed onset muscle soreness (DOMS), functional performance (unilateral vertical jump), and clinical discomfort. The study seeks to determine if PBM can effectively modulate NMES-induced fatigue and muscle damage, potentially optimizing its clinical application.",[538,30,539,540,541],"Photobiomodulation","Discomfort","Electrical Stimulation","Muscle Damage",[538,30,539,541,543],"Electrical stimulation","2026-06-24",{"date":546,"type":41},"2026-06-25",{"date":548,"type":23},"2026-06-01",{"date":470,"type":23},{"name":551,"class":48},"Federal University of Rio Grande do Sul",{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":559,"targetDuration":4,"studyType":24,"phases":561,"briefSummary":562,"conditions":563,"keywords":565,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":569,"lastUpdatePostDateStruct":570,"startDateStruct":572,"completionDateStruct":573,"leadSponsor":575,"locationsCount":49},"100490275","the-safety-and-efficacy-of-redsenol-1-plus-on-cancer-related-fatigue-in-adults-100490275","NCT05664009","The Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults","A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of Redsenol-1 Plus on Cancer-related Fatigue in Adults","Inclusion Criteria:\n\n1. Males and females ≥18 years of age\n2. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n3. Individuals previously diagnosed with cancer and have CRF defined as a score of ≥4 on the CRF Single-Item Scale (an 11-point scale where 0 is \"no fatigue\" and 10 is \"as bad as it can be\")\n4. CRF present for at least one month prior to screening\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score ≤2\n6. Hemoglobin level of ≥110 g\u002FL for females and ≥129 g\u002FL for males at screening\n7. Agrees to maintain current lifestyle habits as much as possible throughout the study depending on ability to maintain the following: diet, medications, supplements, exercise, and sleep and avoid taking new supplements during the study period\n8. Provided voluntary, written, informed consent to participate in the study\n9. Otherwise healthy as determined by medical history and laboratory results as assessed by Qualified Investigator (QI) while taking into consideration the participant's cancer history\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance to the investigational product's or placebo's active or inactive ingredients\n3. Individuals with any CNS malignancies (e.g., brain or spine) and\u002For estrogen-receptor positive breast cancer\n4. Individuals with other primary causes of fatigue, as assessed by the QI (e.g., diagnosed non-cancer related chronic pain, insomnia\u002Fsleep disorders, depression\u002Fpsychiatric disorders, unstable hypothyroidism, diabetes, gastrointestinal disease or symptoms that can affect nutritional balance)\n5. Individuals with unstable medical conditions as assessed by the QI\n6. Individuals with current untreated\u002Funcontrolled high blood pressure or tachycardia\u002Fheart rhythm disorders\n7. Individuals with \\>7.5% HbA1c with treatment for high blood sugar\u002Fdiabetes or individuals with ≥6.5% HbA1c without treatment\n8. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n9. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n10. Major non-cancer surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n11. Current use of prescription\u002FOTC medications and\u002For supplements and food\u002Fdrinks which may affect the efficacy and\u002F or safety of the IP (see Sections 5.4.1 and 5.4.2)\n12. Alcohol or drug abuse within the last 12 months\n13. Frequent (daily) and chronic cannabis users. Occasional (e.g., once per month) cannabis users may be included at the discretion of the QI and if eligible, asked to stop cannabis use for study period\n14. Clinically significant abnormal laboratory results inclusive of thyroid stimulating hormone at screening as assessed by the QI\n15. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n16. Individuals who are unable to give informed consent\n17. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",{"count":560,"type":23},72,[26],"The primary objective of this study is to evaluate the safety and efficacy of Redsenol-1 Plus on cancer-related fatigue (CRF) in adults. The change in the severity of CRF from baseline at week 12 will be assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) fatigue subscale, and compared between Redsenol-1 Plus and placebo groups. Additionally, the safety and tolerability of Redsenol-1 Plus, as compared to placebo, will be measured by the occurrence of and\u002For changes in treatment-emergent adverse events (AEs).",[30,564],"Cancer, Treatment-Related",[566,567,568],"Safety and efficacy","Cancer-related fatigue","Ginseng","2026-06-23",{"date":571,"type":41},"2026-06-26",{"date":189,"type":23},{"date":574,"type":23},"2026-12",{"name":576,"class":117},"Canada Royal Enoch Phytomedicine Co., Ltd.",{"id":578,"slug":579,"hasResults":12,"nctId":580,"briefTitle":581,"officialTitle":582,"acronym":583,"eligibilityCriteria":584,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":585,"targetDuration":4,"studyType":24,"phases":587,"briefSummary":588,"conditions":589,"keywords":591,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":596,"lastUpdatePostDateStruct":597,"startDateStruct":598,"completionDateStruct":600,"leadSponsor":602,"locationsCount":604},"100643932","phase-3-evaluation-of-nuvastatictm-in-reducing-cancer-related-fatigue-in-stage-iv-colon-cancer-patients-undergoing-first-line-chemotherapy-100643932","NCT07669519","Evaluation of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy","Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NuvastaticTM in Reducing Cancer-Related Fatigue in Stage IV Colon Cancer Patients Undergoing First-Line Chemotherapy","NuvastaticTM","Inclusion Criteria:\n\n1. Male and female Patients who are ≥18 and ≤65 years of age, who are willing to voluntarily provide consent for participation in the study.\n2. Patients with colon cancer planned or scheduled to receive standard chemotherapy treatment for at least 3 cycles respectively.\n3. Patients must have a confirmed diagnosis of colon cancer as per standard guideline.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at Screening.\n5. The patient has stable haemoglobin (≥ 9 g\u002FdL) throughout the screening.\n6. Life expectancy ≥ 6 months, as per Investigator's judgment\n7. Patients with co-morbidities or medical conditions including Type 2 DM, hypertension and are deemed stable by the investigator can be included in the study\n8. At screening patients with stable fatigue, has a newly developed fatigue OR worsening of fatigue scoring as assessed by BFI should be included.\n9. Starting first-line chemo\n\nExclusion Criteria:\n\n1. Patients who have any untreated reversible medical condition which may cause fatigue (e.g. metabolic disturbance, infection, endocrine abnormalities) as per the Investigator's clinical judgment.\n2. Patients who have stage IV Disease\n3. Patients who have received concurrent stimulant medication (e.g. dextroamphetamine or methylphenidate) during the screening period or any medication which may interfere with study drug.\n4. Prior metastatic chemo, targeted\u002Fimmunotherapy, severe comorbidities\n5. Female patients who are pregnant or breast-feeding.\n6. Patients with known hepatitis C virus, hepatitis B virus, HIV infection.\n7. Patients who have nausea and vomiting or any gastrointestinal disorder that is severe enough to interfere with study drug absorption in the opinion of the Investigator.\n8. Patients with uncontrolled pain, who in the opinion of the Investigator are not eligible for the study. '\n9. Patients with planned therapy or treatment with another investigational agent.\n10. Previous exposure to any investigational agent within 4 weeks prior to screening, or planned administration of an Investigational agent, other than as specified by this protocol, during the study period.",{"count":586,"type":23},180,[97],"The goal of this clinical trial is to evaluate whether Nuvastatic can reduce cancer-related fatigue in adult patients with colon cancer undergoing first-line chemotherapy.\n\nThe main questions it aims to answer are:\n\nDoes Nuvastatic significantly reduce cancer-related fatigue compared to placebo? Is Nuvastatic safe and well tolerated in this patient population?\n\nResearchers will compare Nuvastatic vs placebo to see if Nuvastatic improves fatigue scores and maintains an acceptable safety profile.\n\nParticipants will:\n\nReceive Nuvastatic or placebo sachets (3 times per day) for 3 cycles of 20 days each (total \\~60 treatment days).\n\nContinue their standard first-line chemotherapy regimen. Provide blood samples for biomarkers (CEA, CA-125) at Screening and End of Treatment.\n\nComplete patient diaries and fatigue assessments as per protocol.",[30,590],"Colon Cancer",[590,592,593,594,595],"Cancer-Related Fatigue","Nuvastatic","Randomized Double-Blind Placebo-Controlled Trial","First-Line Chemotherapy","2026-06-22",{"date":546,"type":41},{"date":599,"type":41},"2025-08-18",{"date":601,"type":23},"2027-03-31",{"name":603,"class":117},"Natureceuticals Sdn Bhd",6,{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":611,"eligibilityCriteria":612,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":613,"targetDuration":4,"studyType":374,"phases":4,"briefSummary":614,"conditions":615,"keywords":624,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":473},"100637471","balance-gait-and-motion-analysis-in-multiple-sclerosis-100637471","NCT07630311","\"Balance, Gait, and Motion Analysis in Multiple Sclerosis\"","\"Functional Assessment of Balance and Gait and Correlation With Kinetic and Kinematic Parameters in Patients With Multiple Sclerosis: Cross-Sectional Study\"","MS-BALGAIT","Inclusion Criteria:\n\n* Adults (≥ 18 years) with confirmed diagnosis of Multiple Sclerosis\n* Expanded Disability Status Scale (EDSS) score \\\u003C6\n* Ability to ambulate independently without the use of assistive devices\n* Absence of significant orthopedic or neurological conditions affecting mobility\n* Ability to understand and follow verbal instructions.\n\nExclusion Criteria:\n\n* History of injury or surgical intervention to the lower limbs or spine within the past year\n* Any musculoskeletal, neurological, cardiovascular, or other medical condition, other than Multiple Sclerosis, that may significantly affect gait or balance or compromise participant safety during testing.\n* Severe balance impairment or high risk of falling that prevents safe participation in single-leg stance, gait analysis, or obstacle negotiation tasks.",{"count":347,"type":23},"The goal of this observational cross-sectional study is to investigate the relationship between functional measures of balance and gait and objective kinetic and kinematic parameters in people with Multiple Sclerosis (MS).\n\nThe main questions it aims to answer are:\n\ni) What is the relationship between kinetic and kinematic gait and balance parameters measured using the Vicon motion analysis system and performance on clinical functional assessments in people with Multiple Sclerosis?\n\nii) Which biomechanical parameters are most strongly associated with functional balance, gait, and physical performance outcomes?\n\nParticipants will attend a single laboratory-based assessment session. During this session, they will undergo biomechanical gait and balance analysis using the Vicon motion capture system, complete functional assessments of balance, gait, and physical performance, complete questionnaires assessing fear of falling and fatigue, and undergo assessment of lower-limb spasticity.",[616,617,185,618,619,620,621,622,30,623],"Multiple Sclerosis","Gait Disorders, Neurologic","Motion Analysis","Biomechanics","Kinetics","Kinematics","Physiotherapy","Fall",[616,625,626,618,627,628,629,30,619],"Balance","Gait","Vicon System","Functional Assessments","Physical Performance","2026-06-21",{"date":544,"type":41},{"date":633,"type":41},"2025-09-01",{"date":635,"type":23},"2026-08-30",{"name":637,"class":48},"University of Patras",{"id":639,"slug":640,"hasResults":12,"nctId":641,"briefTitle":642,"officialTitle":643,"acronym":4,"eligibilityCriteria":644,"healthyVolunteers":58,"sex":18,"minAge":20,"maxAge":645,"enrollmentInfo":646,"targetDuration":4,"studyType":374,"phases":4,"briefSummary":648,"conditions":649,"keywords":654,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":49},"100643936","cognitive-reserve-and-post-fatigue-recovery-in-older-adults-100643936","NCT07667985","Cognitive Reserve and Post-Fatigue Recovery in Older Adults","Determining the Post-Physical and Mental Fatigue Recovery Perspectives of Older Adults Based on Their Cognitive Reserves","Inclusion Criteria:\n\n* being 65 years of age or older,\n* not having any neurological, psychiatric, or systemic disease that would affect one's mental state, and not using any medication for these conditions.\n\nExclusion Criteria:\n\n* Being younger than 65 years old,\n* having an illness or taking medication that affects mental health, or being\n* unable to complete the questionnaires.","90 Years",{"count":647,"type":23},400,"As people grow older, it is common to experience a drop in physical stamina and memory functions. This can make recovering from daily physical and mental fatigue more difficult, which directly impacts an individual's independent daily life and overall quality of life.\n\n\"Cognitive reserve\" is a term that describes the brain's built-in resilience. Built over a lifetime through education, work, and social activities, a higher cognitive reserve acts like a buffer, helping the brain adapt to stress and aging. While research shows that a high cognitive reserve protects against conditions like dementia, we still do not fully understand how it helps older adults bounce back from normal, everyday physical and mental exhaustion.\n\nThe goal of this study is to investigate how cognitive reserve levels influence how individuals aged 65 and older perceive their recovery after experiencing physical and mental fatigue.\n\nWhat the Study Involves\n\nThe researchers will evaluate participants aged 65 and older to measure their baseline cognitive reserve levels. The study will look closely at how these levels affect the participants':\n\nAbility to cope with daily physical and mental fatigue. Need for rest and rest patterns. Time and ability to return to normal daily activities. Overall perception of their mental and physical recovery. Expected Outcome By understanding this relationship, the study aims to fill a gap in medical literature and help healthcare providers design better, more personalized rehabilitation and lifestyle support programs to improve the quality of life for older adults.",[650,651,652,30,653],"Cognitive Reserve","Aging","Mental Fatigue","Recovery of Function",[655,656,108,657],"aging","cognitive reserve","Post-Fatigue Recovery","2026-06-19",{"date":546,"type":41},{"date":661,"type":41},"2026-06-20",{"date":663,"type":23},"2026-09-22",{"name":665,"class":48},"Uşak University",{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":672,"eligibilityCriteria":673,"healthyVolunteers":12,"sex":18,"minAge":674,"maxAge":675,"enrollmentInfo":676,"targetDuration":4,"studyType":24,"phases":678,"briefSummary":679,"conditions":680,"keywords":682,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":686,"startDateStruct":687,"completionDateStruct":689,"leadSponsor":690,"locationsCount":49},"100514337","dietary-intervention-to-mitigate-post-acute-covid-19-syndrome-100514337","NCT05977179","Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome","A Diet Intervention Study To Mitigate Fatigue Symptoms And To Improve Muscle And Physical Function In Older Adults With Post-Acute COVID-19 Syndrome","Long-COVIDiet","Inclusion Criteria:\n\n1. Age of 50 years or older\n2. No known active infectious disease (COVID-19 or other).\n3. Participant diagnosed with long-COVID\u002F post- acute COVID-19 syndrome (PACS) \u002FICD-10-CM codes U09.9\n4. Moderate\u002Fsevere fatigue Brief Fatigue Inventory (BFI)≥4\n5. Poor diet quality assessed by the short Healthy Eating Index (HEI)\\\u003C70\n\nExclusion Criteria:\n\n1. Participants with a home oxygen requirement or requiring chronic ventilator support\n2. Participants diagnosed with diabetes who do not have a recent HbA1c level or with HbA1c \\> 9%\n3. Participants diagnosed with Congestive Heart Failure (CHF New York Heart Association) \\> class 2\n4. Participants with dietary restrictions due to medication use that affects blood clotting, such as Warfarin or other reasons.\n5. Evidence of any condition as determined by a physician or the study team that would lead to an increased risk of illness due to any aspect of proposed testing and interventions, or introduce unanticipated confounding of study results.\n6. Participants diagnosed with uncontrolled hypertension that will be defined as:\n\n   1. Systolic blood pressure consistently equal to or higher than 190 mmHg.\n   2. Diastolic blood pressure consistently equal to or higher than 110 mmHg.\n   3. Participants with a recent history of hypertensive crisis (severe elevation in blood pressure requiring immediate medical intervention), regardless of current blood pressure levels.\n7. Participants with diet restrictions or allergies that can affect adherence to the diet, such as allergy to fish or shellfish.\n8. Participation in another trial in which active intervention is being received.\n9. Participants with active drug or alcohol use\u002Fdependence that would interfere with adherence to the study.\n10. Participants scheduled for surgical procedures within the next 6 months.\n11. Participants diagnosed with active cancer.\n12. Participants diagnosed with liver diseases.\n13. Participants diagnosed with kidney-related conditions, including Chronic Kidney Disease (CKD) \\> stage 3.\n14. Below the age of 50 years.","50 Years","94 Years",{"count":677,"type":23},56,[26],"The primary objective of this study is to conduct a 16-week randomized controlled trial aimed at investigating the effectiveness of the Whole-Diet Approach when following a healthy US-style diet rich in anti-inflammatory properties. The study will focus on evaluating its impact on reducing symptoms related to Post-Acute Sequelae of SARS-CoV-2 Infection (PACS) in adults aged 50 years and older.\n\nThe main research questions this study aims to answer are:\n\n1. Does adhering to a healthy US-style diet, which is abundant in anti-inflammatory properties, effectively mitigate fatigue symptoms in adults with PACS?\n2. Does adhering to a healthy US-style diet, which is abundant in anti-inflammatory properties, effectively mitigate declines in muscle function and physical performance in adults with PACS?\n\nAt the beginning of the study, eligible participants will be randomly assigned to either the Dietary Intervention Group, where they will receive personalized dietary plans and weekly sessions, or the Attention Control Group, where they will attend general health sessions on a weekly basis as well.\n\nThis research intends to shed light on the potential benefits of the Whole-Diet Approach and its role in ameliorating PACS-related symptoms among older adults. By comparing the outcomes of the two groups, we hope to gain valuable insights into the effectiveness of this dietary intervention in improving the quality of life for individuals dealing with PACS.",[681,30],"Post-Acute COVID-19 Syndrome",[683,684,685],"COVID","long-COVID","DIET",{"date":569,"type":41},{"date":688,"type":41},"2025-05-12",{"date":315,"type":23},{"name":691,"class":48},"University of Maryland, Baltimore",{"id":693,"slug":694,"hasResults":12,"nctId":695,"briefTitle":696,"officialTitle":697,"acronym":4,"eligibilityCriteria":698,"healthyVolunteers":58,"sex":18,"minAge":176,"maxAge":20,"enrollmentInfo":699,"targetDuration":4,"studyType":374,"phases":4,"briefSummary":701,"conditions":702,"keywords":707,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":718,"lastUpdatePostDateStruct":719,"startDateStruct":720,"completionDateStruct":722,"leadSponsor":724,"locationsCount":49},"100644217","non-invasive-sleep-monitoring-for-burnout-and-retention-risk-in-postgraduate-nurses-100644217","NCT07666633","Non-Invasive Sleep Monitoring for Burnout and Retention Risk in Postgraduate Nurses","Development of a Non-Invasive Sleep-Based Prediction Platform for Burnout and Retention Risk Among Postgraduate Nurses: A Psychophysiological and AI-Driven Approach for High-Stress Clinical Populations","Inclusion Criteria:\n\n* Newly employed postgraduate nurses within the first 3 months of clinical practice\n* Age 20 to 65 years\n* Full-time clinical nursing staff\n* Able to read and complete Chinese questionnaires\n* Willing to participate in repeated psychological assessments and non-invasive sleep monitoring\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Diagnosed severe sleep disorders\n* Diagnosed severe psychiatric disorders\n* Current use of medications that significantly affect sleep or autonomic nervous system function\n* Inability to comply with longitudinal follow-up procedures\n* Inability to complete repeated sleep monitoring assessments",{"count":700,"type":23},100,"Newly graduated nurses often experience high levels of psychological stress, sleep disturbance, fatigue, and burnout during the early transition into clinical practice. Early identification of burnout and retention risk may help improve mental well-being, workforce stability, and quality of patient care.\n\nThis longitudinal observational study aims to develop a non-invasive sleep-based prediction platform for assessing burnout and retention risk among postgraduate nurses. Participants will undergo repeated psychological assessments and non-contact sleep monitoring during the study period. Sleep-related physiological parameters, including sleep efficiency, sleep structure, heart rate variability, and respiratory variability, will be collected together with validated psychological questionnaires.\n\nThe study will further apply machine learning and artificial intelligence approaches to integrate longitudinal physiological and psychological data for risk prediction and early identification of burnout-related conditions. The findings may support future development of precision mental health monitoring and supportive management strategies for high-stress healthcare workers.",[703,294,704,705,706,30],"Burnout","Occupational Stress","Mental Health","Nurse Retention",[708,709,710,711,712,713,714,715,716,717],"Postgraduate Nurses","Non-Invasive Sleep Monitoring","Burnout Risk","Retention Risk","Artificial Intelligence","Machine Learning","Sleep Quality","Heart Rate Variability","Shift Work","Psychological Stress","2026-06-18",{"date":544,"type":41},{"date":721,"type":23},"2026-08-01",{"date":723,"type":23},"2027-04-23",{"name":725,"class":48},"Kaohsiung Armed Forces General Hospital"]